From January 1, 2024 to March 31, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 9,991,026 shares, representing 16.77% for $1,358.79 million under the buyback announced on November 8, 2016.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
106.1 USD | +2.67% |
|
+5.49% | -13.75% |
10/07 | Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer | CI |
09/07 | RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.75% | 6.69B | |
+61.53% | 848B | |
+38.95% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+5.89% | 234B | |
+16.53% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.